2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS

(19)

(11)

EP 1 259 487 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	23.04.2014 Bulletin 2014/17

(45)	Mention of the grant of the patent:
	23.12.2009 Bulletin 2009/52

(21)	Application number: 01946854.5

(22)	Date of filing: 25.01.2001

(51)

International Patent Classification (IPC):

C07D 213/82^(2006.01)
C07D 401/14^(2006.01)
A61P 35/00^(2006.01)

C07D 213/89^(2006.01)
A61K 31/455^(2006.01)

(86)	International application number:
	PCT/EP2001/000835

(87)	International publication number:
	WO 2001/055114 (02.08.2001 Gazette 2001/31)

(54)	2-AMINO-NICOTINAMIDE DERIVATIVES AND THEIR USE AS VEGF-RECEPTOR TYROSINE KINASE INHIBITORS 2-AMINONICOTINAMID-DERIVATE UND IHRE VERWENDUNG ALS VEGF-REZEPTOR TYROSIN-KINASE INHIBITOREN DERIVES DE 2-AMINO-NICOTINAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE TYROSINE KINASE DU RECEPTEUR VEGF

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
	Designated Extension States:
	RO SI

(30)

Priority:

27.01.2000 GB 0001930

(43)	Date of publication of application:
	27.11.2002 Bulletin 2002/48

(60)	Divisional application:
	09179064.2 / 2168948

(73)	Proprietor: Novartis AG
	4056 Basel (CH)

(72)	Inventors:
	MANLEY, Paul, William CH-4144 Arlesheim (CH) BOLD, Guido CH-5073 Gipf-Oberfrick (CH)

(74)	Representative: Gros, Florent
	Novartis AG Corporate Intellectual Property, Patent & Trademark Department CH 4002 Basel 4002 Basel (CH)

(56)

References cited: :

EP-A- 0 393 529
WO-A-98/07726

WO-A-00/62778
WO-A-99/62885

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).